



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

of 2

Complete if Known

Application Number	10/611,459
Filing Date	July 1, 2003
First Named Inventor	Keith Robert Hildebrand
Group Art Unit	1616
Examiner Name	T/B/D
Attorney Docket Number	11738.00161

Attorney Docket Number 11738.0016

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

**Examiner
Signature**

S Kennedy

**Date
Considered**

217105

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Application's unique citation designation number (optional). ² See *Kinds Codes of USPTO Patent Documents* at www.uspto.gov or MPEP 901.04.

¹ Applicant's unique citation designation number (optional). See Kind Codes of USPTO Patent Documents at [www.uspto.gov](#).
² Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		<i>Complete if Known</i>	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		Application Number	10/611,459
		Filing Date	July 1, 2003
		First Named Inventor	Keith Robert Hildebrand
		Group Art Unit	1616
		Examiner Name	Unassigned
Sheet	2	of	2
		Attorney Docket Number	
		11738.00161	


OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Signature	S Kennedy	Date Considered	2/1/05
--------------------	-----------	-----------------	--------

***EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0851-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

~~DO NOT USE~~
**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Substitute for form 1449A/PTO MAILED INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		Complete If Known	
Sheet	/	of	/
		Application Number	10/611,459
		Filing Date	July 1, 2003
		First Named Inventor	Keith Robert Hildebrand
		Group Art Unit	Unassigned
		Examiner Name	Unassigned
		Attorney Docket Number	11738.00161

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

Examiner Signature	S Kennedy	Date Considered	2/5/05
-----------------------	-----------	--------------------	--------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04.

³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

SEP 18 2003

PATENT TRADEMARK OFFICE

REGISTRATION

Substitute for form 1449A-1 TRADEMARK

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

1 of 2

Complete if Known

Application Number	10/611,459
Filing Date	July 1, 2003
First Named Inventor	Keith Robert Hildebrand
Group Art Unit	Unassigned
Examiner Name	Unassigned

Attorney Docket Number 11738.00161

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
SK		LEWIS, J.E., S.D.G. STEPHENS, ET AL., "Tinnitus and suicide." July 7, 1993, pgs. 50-54, vol. 19, Clin Otolaryngol.	
		MCFADDEN, D., <i>Tinnitus: Facts, Theories, and Treatments</i> , 1982, pgs. 1-9, National Academy Press, Washington D.C.	
		SATALOFF, J., R.T. SATALOFF, ET AL., "Tinnitus and vertigo in healthy senior citizens without a history of noise exposure." March 1987, pgs. 87-89, vol. 2, Thieme Medical Publishers, Inc., New York, NY	
		AXELSSON, A. and A. RINGDAHL, "Tinnitus-a study of its prevalence and characteristics.", 1989, pgs. 53-56, vol. 23, British Journal of Audiology	
		COLES, R. R. A., THOMPSON, ET AL., "Intra-tympanic injections in the treatment of tinnitus.", 1992, pgs. 240-242, vol. 17, Clin Otolaryngol.	
		DOBIE, R.A., "A review of randomized clinical trials in tinnitus.", <i>The Laryngoscope</i> , August 1999, pgs. 1202-1211, Lippincott Williams & Wilkins, Inc., Philadelphia.	
		LOCKWOOD, A.H., R.J. SALVI, ET AL., "The functional neuroanatomy of tinnitus: Evidence for limbic system links and neural plasticity.", January, 1998, <i>Neurology</i> , pgs. 114-120, vol. 50, American Academy of Neurology.	
		MOLLER, A.R., "Symptoms and signs caused by neural plasticity." <i>Neurological Research</i> , September, 2001, pgs. 565-572, vol. 23, Frontline Publishing Group.	
		DEN HARTIGH, J., C. G. J. M. HILDERS, ET AL., "Tinnitus suppression by intravenous lidocaine in relation to its plasma concentration." <i>Clinical Pharmacology & Therapeutics</i> , October 1993, pgs 415-420, vol. 54 no. 4, Mosby-Year Book, Inc.	
		OCHI, K. and J.J. EGGERMONT, "Effects of salicylate on neural activity in cat primary auditory cortex." <i>Hearing Research</i> , 1996, pgs 63-76, vol. 95, Elsevier Science B.V.	
		CASPARY, D.M., J. C. MILBRANDT, ET AL., "Central Auditory Aging: GABA Changes in the Inferior Colliculus." <i>Experimental Gerontology</i> , 1995, pgs. 349-360, vol. 30 nos. 3/4, Elsevier Science Ltd., USA.	
		MCGEER, E. G. and P. L. MCGEER, "AGE CHANGES IN THE HUMAN FOR SOME ENZYMES ASSOCIATED WITH METABOLISM OF THE CATECHOLAMINES, GABA AND ACETYLCHOLINE." <i>Neurobiology of Aging</i> , 1975, pgs. 287-305, Plenum Press, New York.	
		RAZA, A., J. C. MILBRANDT, ET AL., "Age-Related Changes in Brainstem Auditory Neurotransmitters: Measures of GABA and Acetylcholine Function." <i>Hearing Research</i> , 1994, pgs. 221-230, vol. 77, Elsevier Science B. V.	
		ARAKI, T., H. KATO, ET AL., "Selective changes of neurotransmitter receptors in middle-aged gerbil brain." <i>Neurochem. Int.</i> , 1993, pgs. 541-548, vol. 23 no. 6, Pergamon Press Ltd.	
		MILDBRANDT, J. C., R. L. ALBIN, ET AL., "Age-Related Decrease in GABA _A Receptor Binding in the Fischer 344 Rat Inferior Colliculus." <i>Neurobiology of Aging</i> , 1994, pgs. 699-703, vol. 15 no. 6, Elsevier Science Ltd., USA.	
		MOLLER, A. R., M. B. MOLLER, ET AL., "Some Forms of Tinnitus May Involve the Extralemniscal Auditory Pathway." <i>Laryngoscope</i> , October 1992, pgs. 1165-1171.	
		SZCZEPANIAK, W. S. and A. R. MOLLER, "EFFECTS OF L-BACLOFEN AND D-BACLOFEN ON THE AUDITORY SYSTEM: A STUDY OF CLICK-EVOKED POTENTIALS FROM THE INFERIOR COLICULUS IN THE RAT." <i>Ann Otol Rhinol Laryngol</i> , 1995, pgs. 399-404.	
		SZCZEPANIAK, W. S. and A.R. MOLLER, "Effects of (-) baclofen, clonazepam, and diazepam on tone exposure-induced hyperexcitability of the inferior colliculus in the rat: possible therapeutic implications for pharmacological management of tinnitus and hyperacusis." <i>Hearing Research</i> , 1996, pgs. 46-53, Elsevier Science B.V.	
SK		LEES, A. J., C. R. CLARKE, ET AL., "HALLUCINATIONS AFTER WITHDRAWAL OF BACLOFEN." <i>The Lancet</i> , April 16, 1977.	

SK

	ZAPP, J. J., "Gabapentin for the treatment of tinnitus: A case report." ENT-Ear, Nose & Throat Journal, February 2001, pgs. 114-118.	
	KUZNIECKY, R., S. HO, ET AL., "Modulation of cerebral GABA by topiramate, lamotrigine, and gabapentin in healthy adults." Neurology, February 2002, pgs. 368-372, AAN Enterprises, Inc.	
	PETROFF, O. A., F. HYDER, ET AL., "Effects of Gabapentin on Brain GABA, Homocarnosine, and Pyrrolidinone in Epilepsy Patients." Epilepsia, 2000, pgs. 675-680, Lippincott Williams & Wilkins, Inc., Baltimore.	
	WESTERBERG, B. D., J. B. ROBERTSON, ET AL., "A double-blind placebo-controlled trial of baclofen in the treatment of tinnitus." The American Journal of Otology, 1998, pgs. 898-903, The American Journal of Otology, Inc.	
SEP 18 2003 PATENT & TRADEMARK OFFICE O A P E C K S	COFFEY, R. J., D. CAHILL, ET AL., "Intrathecal baclofen for intractable spasticity of spinal origin: results of a long-term multicenter study." J Neurosurg, February 1993, pgs. 226-232, vol. 78.	
	MEYTHALER, J. M., S. GUIN-RENFROE, ET AL., "CONTINUOUSLY INFUSED INTRATHECAL BACLOFEN FOR SPASTIC/DYSTONIC HEMIPLAGIA." American Journal of Physical Medicine & Rehabilitation, 1999, pgs. 155-161, no. 9, Lippincott Williams & Wilkins, Inc.	
	PENN, R. D., S. M. SAVOY, ET AL., "INTRATHECAL BACLOFEN FOR SEVERE SPINAL SPASTICITY." New England Journal of Medicine, June 8, 1989, pgs. 1571-1572, vol. 320.	
	KNUTSSON, E., U. LINDBLOM, ET AL., "Plasma and Cerebrospinal Fluid Levels of Baclofen (Lioresal®) at Optimal Therapeutic Responses in Spastic Paresis." Journal of the neurological Sciences, 1974, pgs. 473-484, vol. 23, Elsevier Scientific Publishing Company, Netherlands.	
	KROIN, J. S., "Intrathecal Drug Administration." Clin. Pharmacokinet. 1992, pgs. 319-326, vol. 22 (5), Adis International Limited.	
	KROIN, J. S. and R.D. PENN, "Cerebrospinal fluid pharmacokinetics of lumbar intrathecal baclofen", 1991, pgs. 67-77, Parthenon Publishing.	
	MULLER, H., J. ZIERSKI, ET AL. "Pharmacokinetics of Intrathecal Baclofen." 1998, pgs. 223-226, Springer-Verlag.	
	MILBRANDT, JC, ET AL., "GAD levels and muscimol binding in rat inferior colliculus following acoustic trauma." Hearing Research, 2000, pgs. 251-260, vol. 147 (1-2), Elsevier Science B.V.	
	CASPARY, D.M., T.M. HOLDER, ET AL. "AGE-RELATED CHANGES IN GABA _A RECEPTOR SUBUNIT COMPOSITION AND FUNCTION IN RAT AUDITORY SYSTEM." Neuroscience, 1999, pgs. 307-312, vol. 93, Elsevier Science, Ltd.	
	MILBRANDT JC, HUNTER C, ET AL., "Alterations of GABA _A Receptor Subunit mRNA Levels in the Aging Fischer 344 Rat Inferior Colliculus." The Journal of Comparative Neurology, 1997, pgs 455-65, vol. 379, Wiley-Liss, Inc.	
	MILBRANDT JC, ET AL., "GABA _A RECEPTOR BINDING IN THE AGING RAT INFERIOR COLICULUS." Neuroscience, 1998, pgs. 449-458, vol. 73, no. 2, Elsevier Science Ltd., Great Britain.	
	SIMPSON, J.J. ET AL. "Recent advances in the pharmacological treatment of tinnitus." Trends in Pharmacology Sciences, January 1999, vol. 20.	
	JASTREBOFF, P., ET AL., "Neurophysiological approach to tinnitus patients." The American Journal of Otology, 1996, pgs. 236-240, vol. 17, The American Journal of Otology, Inc.	
	MERCHANT, S.N. ET AL., "Vestibular effects of intravenous lidocaine used in the treatment of tinnitus." The Journal of Laryngology and Otology, November 1986, pgs. 1249-1253, vol. 100.	
	PODOSHIN, L. M. ET AL., "Treatment of tinnitus by intratympanic installation of lignocaine (lidocaine) 2 per cent through ventilation tubes." The Journal of Laryngology and Otology, July 1992, pgs. 603-606, vol. 106.	
	RAZA, A., ET AL., "Age-related changes in brainstem auditory neurotransmitters: measures of GABA and acetylcholine function." Hearing Research, 1994, pgs. 221-230, vol. 77, Elsevier Science B.V.	
SK	KALTENBACH, J. A. "Neurophysiologic Mechanisms of Tinnitus." Journal of the American Academy of Audiology, March 2000, pgs. 125-137, vol. 11, no. 3.	

Examiner Signature	SKennealy	Date Considered	2/1/05
--------------------	-----------	-----------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.